Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785....
[6] Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:a meta-analysis [J]. Lancet Diabetes Endocrinol, 2018,6:105-113....
[4]Tucker ME. PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes. Medscape. March 27, 2019. Avaliable at: https://www.medscape.com/viewarticle/910986 Last assessed on 2019-04-08. [5]Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients wi...
是FDA批准的首创新药。GLP-1/GIP双重受体激动剂，相对于选择性GLP-1受体激动剂，表现出更好的血糖控制...
[4]Tucker ME. PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes. Medscape. March 27, 2019. Avaliable at: https://www.medscape.com/viewarticle/910986 Last assessed on 2019-04-08. [5]Marso SP, Bain SC, Consoli A,...
cardiovascular disease,which increases external validity and gives us a high confidence in these estimates.Considering the percentage of coronary artery bypass graftingCABGand percutaneous coronary angioplastyPCIprocedures that are attributable to patients who may benefit from GLP-1s,we calculated a volume ...
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM). However, dose-related gastrointestinal effects limit efficacy, and therefore agents possessing GLP-1 pharmacology that can al...
3. Zareini B, et al. Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes. Presented at ADA2023. 200-LB. 4. Sorli C, et al. Lancet Diabetes Endocrinol. 2017; 5: 251-260. 5. Ahrén B, et al. Lancet Diabetes Endocrinol. 2017; 5: 341...
GLP1 receptor agonists have been proven effective antidiabetic medications with possible cardiovascular benefits. Even though they have been proven to reduce the risk of major adverse cardiovascular events, their effectiveness in treating heart failure is unknown. Unlike traditional GLP1 receptor agonists,...
[4]Tucker ME. PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes. Medscape. March 27, 2019. Avaliable at: https://www./viewarticle/910986 Last assessed on 2019-04-08. [5]Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 ...